眭子健医师 (Zijian Xu，MD, PHD, FACC)
眭子健医师(Zijian Xu，MD, PHD, FACC)
1983 毕业于上海第一医科大学医学系
1983-1984 北京协和医院內科住院医师
1984-1987 北京中日友好医院心内科住院医师
1987-1992 美国迈阿密大学（University of Miami) 心血管细胞与分子药理学博士生及博士后
1992-1995 斯坦福大学(Stanford University)生理系及Howard Hughes Medical Institute 博士后研究员。
1995-1997 加洲大学洛杉矶医学中心(UCLA Medical Center) 住院医师
1997-2000 加洲大学洛杉矶医学中心(UCLA Medical Center)心血管专科培训。
2000-2005 加洲大学洛杉矶医学中心(UCLA Medical Center)心血管科助理教授。
2005-现在 美国加州沙克拉门托赛特医疗中心(Sutter Medical Center Sacramento)心内科。曾任心血管大科主任(chief of cardiovascular department，轮流任期制); 现任心力衰竭科主任：心脏无创检查科（超声心动，心脏核素等检查）主任。
2018-现在 北加州大学医学院和药学院临床教授
专科证书：
美国心血管专家证书
美国重症心衰和心脏移植专家证书
美国心脏核素专家证书
专业协会的参与：
美国心脏病医师协会资深会员（Fellow of American College of Cardiology)
美国心衰协会(Heart Failure Society of America)会员及国际关系委员会委员
美国心脏超声协会(American Society of Echocardiography)会员
世界心肺移植协会(International Society of Heart and Lung Transplant) 会员
美国华人心脏病协会(Chinese American Heart Association, CHANA)终身会员，付会长
美华择业医师协会(Society of Chinese American Physician Entrepreneur, SCAPE)会员，前执委会委员及理事会主席
美国加州华人医师协会(Chinese American Medical Association of California, CAMAC)会员
及前主席
临床工作：
疑难心血管疾病的珍治，重症心衰的诊治，慢性心衰的疾病管理，心衰中心的建立，认证及管理，心室辅助装置和心脏移植的术前评估及术后管理，左右心导管术，冠脉造影，心脏活检术，心脏影像学（超声心动）。获有美国心血管医学，心脏核医学专科证书。
教学：
多年从事医学生，药学院学生，住院医师，护师(nurse practitioner), 和临床医师的临床带教；中国医师在美国和中国的监床带教；CHANA中美远程心血管专科査房；CNAHA中美心血管专科培训基地的教学; SCAPE的家庭全科医师培训项目的远程和现场授课; SCAPE的中美合作内科住院医师规范化培训基地的现场教学等。
科研：
早年从事理子通道的电生理和分子生物学的研究。目前主要参与心血管药物及装置的临床研究。多年来作为 中心负责人（principal investigator)参与几十项大型随机，双盲，多中心的临床研究，包括一些重大的心衰药物、心室辅助装置、及移动式血流动力学检测装置的临床研究。
ZI-JIAN XU, MD, PhD, FACC.
EDUCATION:
M.D.
Shanghai Medical University 1978-1983
Shanghai, People Republic of China
Ph.D. 1987-1991
Cellular and Molecular Pharmacology
University
of Miami, School of Medicine
Miami, Florida
Postdoctoral Fellowship 05/1992-05/1995
Cellular and Molecular Physiology
Stanford University School of Medicine,
Department of Physiology &
Howard Hughes Medical Institute
PROFESSIONAL EXPERIENCE:
Present Position:
Medical Director of Adult In-patient Heart Failure Service 9/2006-present
Medical Director of Non-invasive Cardiac Diagnostics
Sutter Medical Center, Sacramento, CA
Practice Care Center Lead
Sutter Medical Group, Cardiology 11/2009-present
Sacramento, CA
Clinical Associate Professor of Internal Medicine 3/2018-present
California Northstate University College of Medicine
Elk Grove, CA
Clinical Professor 8/2019-present
California Northstate University College of Pharmacy
Elk Grove, CA
Previous Positions:
Chief, Cardiovascular Department 1/2014-12/2015
Sutter Medical Center Sacramento, CA
Northern California Cardiology Associates 7/2005-10/2009
Sacramento, CA
Assistant Clinical Professor 7/2000-6/2005
University of California, Los Angeles (UCLA) Medical Center
Los Angeles, California
Cardiology Fellowship 07/1997-06/2000
UCLA Medical Center
Los Angeles, California
Internal Medicine Residency 07/1996-06/1997
UCLA Medical Center
Los Angeles, California
Internal Medicine Internship 06/1995-06/1996
UCLA Medical Center
Los Angeles, California
Postdoctoral Fellowship 05/1992-05/1995
Stanford University School of Medicine
Howard Hughes Medical Institute & Department of Physiology
Graduate Student & Postdoctoral Fellowship 09/1987-04/1992
University of Miami School of Medicine
Department of Molecular and Cellular Pharmacology
Internal Medicine 09/1984-08/1987
China-Japan Friendship Hospital
Beijing, People’s Republic of China.
Internal Medicine Internship
Peking Union Medical College Hospital 08/1983-08/1984
Beijing, People’s Republic of China
Other Positions:
Vice President, Chinese American Heart Association, USA Current
President, Chinese American Medical Association of California 2014-2016
CLINICAL EXPERTISE AND SKILLS:
Advanced heart failure and transplant cardiology, General consultative cardiology; Cardiac imaging (Transthoracic echocardiography; Transesophageal echocardiography; Stress testing; Nuclear cardiology; & CT angiography), Heart catheterization, coronary angiography, Endomyocardium biopsy
LICENSURE:
Licensed Physician and Surgeon in the State of California 1997
X-ray and Fluoroscopy 2007
CERTIFICATION:
Diplomat, American Board of Internal Medicine, Advanced Heart Failure
and Transplant Cardiology. 2013
Diplomat, Nuclear Cardiology, The Certification Board of Nuclear Cardiology 2012
Diplomat, American Board of Internal Medicine, Cardiovascular Disease2011
Diplomat, American Board of Internal Medicine, Internal Medicine 1998
Educational Commission for Foreign Medical Graduates (ECFMG) 1994
TEACHING EXPERIENCE:
Sutter Medical Center 2005-present
Lectures and preceptorship for Family Medicine residents
California Northstate University College of Medicine 2018-present
Lectures and cardiology preceptorship for medical students
UCLA Medical Center 1997-2005
Conferences and lectures for Medical house-staffs.
UCLA Santa Monica Cardiology/Santa Monica Hospital 2000-2005
Nuclear Myocardial Perfusion/
Coronary Angiography Correlation conference (monthly)
UCLA Santa Monica Cardiology/Santa Monica Hospital 2000-2005
Preceptor for Internal Medicine and Family Medicine residents
Preceptor for Cardiology fellows
UCLA Santa Monica Hospital 2000-2005
Morning conference, ECG conference,
and lectures for Family Medicine residents
UCLA School of Medicine, 1998-2000
Advanced Clinical Skills course for medical students.
Group discussion and demonstration.
UCLA School of Medicine 1998-2000
Physiology 201 Course
EKG & Blood Pressure laboratory for medical students.
Group discussion and demonstration.
UCLA School of Medicine 1998
Neurobiology 201 course for medical students
Microscopic Anatomy & Cell Biology
Laboratory discussion and demonstration
PROFESSIONAL AFFILIATIONS:
Fellow of American College of Cardiology
Heart Failure Society of America ( member of the Committee of International Relations)
International society of heart and lung transplantation
American Society of Echocardiography
Chinese American Heart Association (Vice President)
Chinese American Medical Association of California (former president)
Society of Chinese American Physician Entrepreneurs (former executive committee member and chair of board of directors)
HONORS AND AWARDS:
Best Doctor in Sacramento 2018
Sacramento Magazine
Teacher of the Year
Sutter Health Family Medicine Residency 2013-2014
Teaching Award
UCLA Family Medicine Residency Program 2004
Teaching Award
UCLA Family Medicine Residency Program 2003
Teaching Award
UCLA-Santa Monica Family Medicine Residency Program 2001
Outstanding Teacher of the Year 1997-1998
UCLA Medical House Staff
National Institutes of Health Training Grant (HL07895-01) 1998-2000
Postdoctoral Research Fellowships for Physicians 1992-1995
Howard Hughes Medical Institute
American Medical Association Award for Overall Excellence of Research 1990
31st Annual National Student Research Forum
First Place, Mead Johnson Overall Excellence of Research Awards 1990
31st Annual National Student Research Forum
Dean’s Award for The Most Outstanding Student Presentation 1990
University of Miami
Eastern Student Research Forum
Prize for Key Achievements in Science and Technology 1988
Chinese Department of Health
(Electrocardiographic peak mapping and its applications).
PUBLICATIONS
Haney, S., Sur, D., & Xu, Z-J. (2005). Diastolic Heart Failure: Review and Primary Care Perspective. The Journal of the American Board of Family Practice18:189-198.
Xu, Z-J(2004). Management of diastolic heart failure: principales and evidence. Proceedings of UCLA Healthcare. Vol 8. No. 1, Fall 2004.
Xu, Z-J. & R.W. Aldrich. (1995). Exploring the role of S4-S5 linker region in the activation mechanism of Shaker potassium channels. Biophysical Journal68, A137.
Xu, Z-J. & Adams, D.J. (1993). Alpha-adrenergic modulation of ionic conductances in cultured parasympathetic neurons from rat intracardiac ganglia. Journal of Neurophysiology 69, 1060-1070.
Xu, Z-J.& Adams, D.J. (1992). Resting membrane potential and potassium currents in cultured parasympathetic neurons from rat intracardiac ganglia. Journal of Physiology 456, 405-424.
Xu, Z-J.& Adams, D.J. (1992). Voltage-dependent sodium and calcium currents in cultured parasympathetic neurons from rat intracardiac ganglia. Journal of Physiology 456, 425-441.
Xu, Z-J. & Adams, D. J. (1992). K+ currents contributing to the resting membrane potential and the action potential in rat parasympathetic cardiac neurons. Biophysical Journal. 61, 253a.
Xu, Z-J. & Adams, D. J. (1990). Norepinephrine and GTP-g-S activate a time-independent background current in rat parasympathetic cardiac neurons. Biophysical Journal. 57, 311a
Adams, D. J. & Xu, Z-J. (1989). Norepinephrine and GTP-g-S inhibit a calcium conductance and activate a non-selective cation conductance in rat parasympathetic cardiac neurons. Journal of General Physiology. 94, 1-2a.
Xu, Z-J., Fong, Q.D. & Wen, Y.M. (1988). The construction of isochronic map and its preliminary application. Journal of China-Japan Friendship Hospital. 1(1).
Wen, Y. M., Xu, Z-J. & Fong, Q. D. (1988). Electrocardiographic peak mapping in determining the location and size of myocardial infarction – experience with 61 cases. Chinese Journal of Medicine. 27 (11), 668-72, 715-6 (with English Abstract).
Wen, Y. M., Xu, Z-J., Fong Q. D., Wang, X. Y. & Yei, Q. (1988). Evaluation of QRS peak mapping for the estimation of the localization and the size of myocardial infarction. Clinical Research. 36,116A.
Wen, Y. M., Fong, Q. D., Xu, Z-J., Hu, Z., & Wang, X. (1988). The application of electrocardiographic peak mapping in
diagnosis
of cardiomyopathy. Journal of China-Japan Friendship Hospital.2, 211-216.
RESEARCH TRIALS: SUTTER HEART AND VASCULAR INSTITUTE
Principle Investigator
Cardiomems™ HF System Post Approval Study
Start date – September 2017- Continuing
Life-HF
Entresto™(LCZ696) in Advance Heart Failure (LIFE STUDY)
Start date- April 2017- Continuing
Victoria
A randomized parallel-group,
placebo controlled
, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral
gGC
stimulator
vericiguat
in subjects with heart failure with reduced ejection fraction study
October 2016– Continuing
Paradigm-HF
A multicenter, randomized, double-blind,
parallel group
, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction CLCZ696B2314
Start date May 21, 2010 – Completed
LAPTOP
Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF)
Start date – February, 2012-Completed.
CANTOS Trial
A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP
Start date – April 29, 2011 – Completed
ROCKETAF
A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) with Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System
Systemic Embolism in Subjects with Non-Valvular Atrial
Fibrillati
Completed
Ascend-HF Trial
Double-Blind, Placebo-
Contolled
, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF)(Protocol A 093)
Completed
Protect Trial
A multicenter, randomized, double-blind,
placebo controlled
study of effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in patients with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy
Completed
Rebuild-ADHF Trial
Research of Beta Blocker Utilization In Longitudinal Database in Heart Failure in Patients Hospitalized for Acute Heart Failure, A Multi-Center, Prospective, Observational Acute Heart Failure Registry Study.
Completed
Red-HF Trial
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin
alfa
Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Completed
Red-HF Sub-study Trial
Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Effect of Darbepoetin alfa Treatment on Cardiac Function and
Disease Specific
Biomarkers in Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia: An Exploratory Sub-study for the RED-HF™ (Reduction of Events with Darbepoetin alfa in Heart Failure) Trial
Completed
Sub-Investigator
CONNECT-HF
Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure
Start date – July 26, 2018 – Continuing
MOMENTUM 3 CAP
Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3™ Continued Access Protocol.
Start date – October 17, 2016 – Continuing
SOPRANO
A prospective
,multicenter
, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of
macitentan
in patients with pulmonary hypertension after left ventricular assist device implantation
Start date – April 20, 2016 – Continuing
Cardiomems-HF System Post Approval Study
Start date – May 28, 2015 – Continuing
ALERTS
AngelMed
ST-monitoring Device for Early Recognition and Treatment of STEMI.
Start date – October 24, 2008 – Completed
Inovate-HF Trial
INcrease Of VAgal TonE in chronic Heart Failure – A PIVOTAL TRIAL TO ESTABLISH THE LONG-TERM SAFETY AND EFFICACY OF THE
CARDIOFIT
SYSTEM
Start date – March 25, 2011-Completed
Analyze-ST–This is a prospective, non-randomized, multicenter, pivotal IDE study
evaluating the
Fortify®ST ICD system (or other ICD systems with the ST Monitoring Feature).
Start date – September 23, 2011 – Completed
Mometum 3Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with
HeartMate 3™
Start date – May 31, 2016 – Completed
GUIDE-IT
BNP directed
out patient
therapy for heart failure patients.
Start date 2013- Completed
HF-Action (UCLA)
HF-ACTION was designed to determine whether a tailored exercise program can help heart failure patients live longer. The trial was sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the Federal Government’s National Institutes of Health (NIH) and was conducted at approximately 50 different sites in the U.S. and Canada.
Completed
